Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial - Poll - MDSpire

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

  • By

  • Mengyao Liu

  • Zengjun Liu

  • Jing Xu

  • Xin Xu

  • Qibing Wu

  • Dongyuan Zhu

  • June 8, 2026

  • 0 min

Share

Original Source(s)

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

  • by Mengyao Liu, Zengjun Liu, Jing Xu, Xin Xu, Qibing Wu, Dongyuan Zhu

  • June 8, 2026

Related Content

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial

Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes